Small-Molecule Tyrosinase Inhibitors for Treatment of Hyperpigmentation
Guardat en:
| Publicat a: | Molecules vol. 30, no. 4 (2025), p. 788 |
|---|---|
| Autor principal: | |
| Altres autors: | , , , |
| Publicat: |
MDPI AG
|
| Matèries: | |
| Accés en línia: | Citation/Abstract Full Text + Graphics Full Text - PDF |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3171127841 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1420-3049 | ||
| 024 | 7 | |a 10.3390/molecules30040788 |2 doi | |
| 035 | |a 3171127841 | ||
| 045 | 2 | |b d20250101 |b d20251231 | |
| 084 | |a 231541 |2 nlm | ||
| 100 | 1 | |a Ni, Xinhua |u School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China; Key Laboratory of Elemene Class Anti-Tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, China | |
| 245 | 1 | |a Small-Molecule Tyrosinase Inhibitors for Treatment of Hyperpigmentation | |
| 260 | |b MDPI AG |c 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Increasing attention is being focused on skin health currently, especially the excessive deposition of melanin in the skin. Tyrosinase, the rate-limiting enzyme in melanin biosynthesis, is a crucial enzyme in melanin synthesis. However, existing tyrosinase inhibitors pose some degree of toxicity to humans. Therefore, the development of more efficient and low-toxicity tyrosinase inhibitors is urgently needed. This review briefly depicts the melanin biosynthesis process and the crystal structure and catalytic mechanism of tyrosinase. The latest research progress regarding small-molecule tyrosinase inhibitors is also reviewed. Moreover, the structure–function relationships are analyzed and summarized. This is expected to provide new and more scientific insights to enable researchers to explore safer and more potent tyrosinase inhibitors. | |
| 653 | |a Crystal structure | ||
| 653 | |a Physiology | ||
| 653 | |a Copper | ||
| 653 | |a Medical prognosis | ||
| 653 | |a Metastasis | ||
| 653 | |a Melanoma | ||
| 653 | |a Oxidation | ||
| 653 | |a Enzymes | ||
| 653 | |a Kinases | ||
| 653 | |a Radiation therapy | ||
| 653 | |a Biosynthesis | ||
| 653 | |a Skin cancer | ||
| 653 | |a Proteins | ||
| 653 | |a Molecules | ||
| 700 | 1 | |a Luo, Xinyu |u School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China; Key Laboratory of Elemene Class Anti-Tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, China | |
| 700 | 1 | |a Jiang, Xiaoying |u School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China; Key Laboratory of Elemene Class Anti-Tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, China | |
| 700 | 1 | |a Chen, Wenchao |u School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China; Key Laboratory of Elemene Class Anti-Tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, China | |
| 700 | 1 | |a Bai, Renren |u School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China; Key Laboratory of Elemene Class Anti-Tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, China | |
| 773 | 0 | |t Molecules |g vol. 30, no. 4 (2025), p. 788 | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3171127841/abstract/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text + Graphics |u https://www.proquest.com/docview/3171127841/fulltextwithgraphics/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3171127841/fulltextPDF/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |